Evolus, INC Form 4 insider transactions

David Moatazedi, President and CEO of Evolus, Inc., reports acquisition of shares, performance-based restricted stock units, and stock options.

Rui Avelar, Chief Medical Officer and Head of R&D at Evolus, Inc., reports transactions involving common stock, restricted stock units, performance-based restricted stock units, and stock options.

Director Simone Blank reports acquisition of Evolus, Inc. stock and stock options, along with indirect ownership details.

Director David N. Gill reports acquisition of Evolus, Inc. shares and stock options, signaling potential confidence in the company's future.

Director Brady Stewart reports acquisition of Evolus, Inc. shares and stock options, signaling potential confidence in the company's future.

Director Albert G. White III reports changes in beneficial ownership of Evolus, Inc. stock, including acquisition of restricted stock units and stock options, as well as disposal of common stock.

Director Vikram Malik reports acquiring and disposing of Evolus, Inc. shares and acquiring stock options.

Director Karah Parschauer reported the acquisition of restricted stock units and stock options in Evolus, Inc.

Evolus Inc.'s Chief Medical Officer, Rui Avelar, sold 2,252 shares of common stock to cover tax obligations related to vesting restricted stock units.

Evolus, Inc. CFO Sandra Beaver sold 1,586 shares of common stock on December 23, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Evolus Inc. CEO David Moatazedi sold 10,502 shares of common stock on December 23, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Evolus CFO Sandra Beaver sold 3,276 shares of common stock on September 6, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Tomoko Yamagishi-Dressler, Chief Marketing Officer of Evolus Inc., sold 5,631 shares of common stock on August 30, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director Albert G. White III acquired 23,014 shares of Evolus, Inc. common stock on July 1, 2024, through the settlement of restricted stock units (RSUs).

Evolus, Inc. CEO David Moatazedi exercised stock options and sold shares of common stock over three days in early June 2024.

Director Vikram Malik sold 7,500 shares of Evolus, Inc. (EOLS) at an average price of $12.9604 on June 3, 2024.

Director David N. Gill of Evolus, Inc. [EOLS] recently sold shares of common stock in multiple transactions on May 13 and May 14, 2024.

Director Vikram Malik sold 28,000 shares of Evolus, Inc. (EOLS) common stock at an average price of $12.929 on May 13, 2024.

Evolus, Inc. CEO David Moatazedi sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Rui Avelar, Chief Medical Officer & Head of Research and Development at Evolus, Inc., sold shares to cover tax withholding obligations related to vesting restricted stock units.

Evolus Inc.'s CFO, Sandra Beaver, sold 2,423 shares of common stock on May 10, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Evolus, Inc. CEO David Moatazedi sold 6,236 shares of common stock on March 27, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Rui Avelar, Chief Medical Officer & Head of Research and Development at Evolus, Inc., sold 27,603 shares of common stock on March 19, 2024, to cover tax withholding obligations related to Restricted Stock Units.

Evolus CFO Sandra Beaver sold 5,672 shares of common stock on March 19, 2024, to cover tax withholding obligations related to restricted stock units.

David Moatazedi, President & CEO of Evolus, Inc., sold 96,566 shares of common stock on March 19, 2024, to cover tax withholding obligations related to restricted stock units.